FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2104653304> ?p ?o ?g. }

• W2104653304 abstract "Systemic juvenile idiopathic arthritis (SoJIA) is the most striking form of juvenile idiopathic arthritis. The aim of our study was to evaluate the clinical responses and outcomes of children with SoJIA to IL-6 blockade using two different tocilizumab (TCZ) treatment protocols designed for milder and more severe SoJIA patient groups, and evaluate the possibility of achieving biologic-free remission. Thirty-seven active SoJIA children who have failed treatment with corticosteroids and other DMARDs were included in our retrospective study. TCZ doses were prescribed in two treatment approaches: every 2 weeks TCZ dosing (Q2W) and every 4 weeks TCZ dosing (Q4W). The patients were assigned to these two groups by the study physicians depending on the severity of the SoJIA disease as judged by each clinician. Thirty-three of the 37 children successfully completed the trial. TCZ was discontinued in 11patients during the trial. Seven children achieved inactive disease and were allowed to stop the TCZ and 4 had severe adverse events requiring drug cessation. Currently 7 patients continue to have TCZ-free remission [4/7 remission off-medication, 3/7still on methotrexate (MTX)]. This mixed group had a median treatment duration of 1002 days. The children in remission off of all medications, TCZ and MTX, had a median remission duration of 1162 days (ranged 932–1301 days). Compared to the patients assigned to the Q2W TCZ treatment group, the patients assigned to the Q4W TCZ group had a milder SoJIA course. The patients had higher levels of hemoglobin, total proteins, and serum albumins. They had lower white blood cell counts (WBC), % granulocytes, CRP, ESR, ferritins, and LDH. These children had a lower frequency of internal organ involvement, fewer relapses during TCZ treatment, and no macrophage activation syndrome episodes. Our experience with TCZ for SoJIA supports the excellent result of other studies. What may be novel is our finding that thisIL-6 blockade with TCZ may be able to be utilized at a less frequent dosing schedule in mild SoJIA compared to severe SoJIA. We discuss other factors that may increase the probability of a patient reaching TCZ-free remission." @default.
• W2104653304 created "2016-06-24" @default.
• W2104653304 creator A5006317525 @default.
• W2104653304 creator A5006479875 @default.
• W2104653304 creator A5027922862 @default.
• W2104653304 creator A5028460018 @default.
• W2104653304 creator A5032811066 @default.
• W2104653304 creator A5038721630 @default.
• W2104653304 creator A5053918516 @default.
• W2104653304 creator A5057813686 @default.
• W2104653304 creator A5069708497 @default.
• W2104653304 creator A5069937130 @default.
• W2104653304 creator A5074405532 @default.
• W2104653304 creator A5090452143 @default.
• W2104653304 date "2015-01-23" @default.
• W2104653304 modified "2023-10-01" @default.
• W2104653304 title "Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis" @default.
• W2104653304 cites W1272091209 @default.
• W2104653304 cites W1632068222 @default.
• W2104653304 cites W1967173230 @default.
• W2104653304 cites W1973033020 @default.
• W2104653304 cites W1974138441 @default.
• W2104653304 cites W1987842727 @default.
• W2104653304 cites W1991716229 @default.
• W2104653304 cites W1994860638 @default.
• W2104653304 cites W2017213437 @default.
• W2104653304 cites W2021579922 @default.
• W2104653304 cites W2025112232 @default.
• W2104653304 cites W2065287600 @default.
• W2104653304 cites W2073700972 @default.
• W2104653304 cites W2087769239 @default.
• W2104653304 cites W2110995918 @default.
• W2104653304 cites W2120852203 @default.
• W2104653304 cites W2125212735 @default.
• W2104653304 cites W2127359359 @default.
• W2104653304 cites W2132024570 @default.
• W2104653304 cites W2150900575 @default.
• W2104653304 cites W2156584537 @default.
• W2104653304 cites W2171799063 @default.
• W2104653304 cites W2221264044 @default.
• W2104653304 cites W2245644176 @default.
• W2104653304 cites W2334971712 @default.
• W2104653304 cites W4246196046 @default.
• W2104653304 doi "https://doi.org/10.1186/1546-0096-13-4" @default.
• W2104653304 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4328569" @default.
• W2104653304 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25685108" @default.
• W2104653304 hasPublicationYear "2015" @default.
• W2104653304 type Work @default.
• W2104653304 sameAs 2104653304 @default.
• W2104653304 citedByCount "11" @default.
• W2104653304 countsByYear W21046533042015 @default.
• W2104653304 countsByYear W21046533042016 @default.
• W2104653304 countsByYear W21046533042017 @default.
• W2104653304 countsByYear W21046533042018 @default.
• W2104653304 countsByYear W21046533042019 @default.
• W2104653304 countsByYear W21046533042022 @default.
• W2104653304 crossrefType "journal-article" @default.
• W2104653304 hasAuthorship W2104653304A5006317525 @default.
• W2104653304 hasAuthorship W2104653304A5006479875 @default.
• W2104653304 hasAuthorship W2104653304A5027922862 @default.
• W2104653304 hasAuthorship W2104653304A5028460018 @default.
• W2104653304 hasAuthorship W2104653304A5032811066 @default.
• W2104653304 hasAuthorship W2104653304A5038721630 @default.
• W2104653304 hasAuthorship W2104653304A5053918516 @default.
• W2104653304 hasAuthorship W2104653304A5057813686 @default.
• W2104653304 hasAuthorship W2104653304A5069708497 @default.
• W2104653304 hasAuthorship W2104653304A5069937130 @default.
• W2104653304 hasAuthorship W2104653304A5074405532 @default.
• W2104653304 hasAuthorship W2104653304A5090452143 @default.
• W2104653304 hasBestOaLocation W21046533041 @default.
• W2104653304 hasConcept C126322002 @default.
• W2104653304 hasConcept C187212893 @default.
• W2104653304 hasConcept C197934379 @default.
• W2104653304 hasConcept C198451711 @default.
• W2104653304 hasConcept C2777077863 @default.
• W2104653304 hasConcept C2777178219 @default.
• W2104653304 hasConcept C2777288759 @default.
• W2104653304 hasConcept C2779134260 @default.
• W2104653304 hasConcept C2781059491 @default.
• W2104653304 hasConcept C71924100 @default.
• W2104653304 hasConceptScore W2104653304C126322002 @default.
• W2104653304 hasConceptScore W2104653304C187212893 @default.
• W2104653304 hasConceptScore W2104653304C197934379 @default.
• W2104653304 hasConceptScore W2104653304C198451711 @default.
• W2104653304 hasConceptScore W2104653304C2777077863 @default.
• W2104653304 hasConceptScore W2104653304C2777178219 @default.
• W2104653304 hasConceptScore W2104653304C2777288759 @default.
• W2104653304 hasConceptScore W2104653304C2779134260 @default.
• W2104653304 hasConceptScore W2104653304C2781059491 @default.
• W2104653304 hasConceptScore W2104653304C71924100 @default.
• W2104653304 hasIssue "1" @default.
• W2104653304 hasLocation W21046533041 @default.
• W2104653304 hasLocation W21046533042 @default.
• W2104653304 hasLocation W21046533043 @default.
• W2104653304 hasLocation W21046533044 @default.
• W2104653304 hasOpenAccess W2104653304 @default.
• W2104653304 hasPrimaryLocation W21046533041 @default.
• W2104653304 hasRelatedWork W1981062313 @default.
• W2104653304 hasRelatedWork W1987294331 @default.
• W2104653304 hasRelatedWork W2221708345 @default.

• next